A phase II study of 4SC-202 in combination with checkpoint inhibitors in pre-treated patients with microsatellite-stable gastrointestinal cancers

Trial Profile

A phase II study of 4SC-202 in combination with checkpoint inhibitors in pre-treated patients with microsatellite-stable gastrointestinal cancers

Planning
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs 4SC 202 (Primary)
  • Indications Gastrointestinal cancer
  • Focus Therapeutic Use
  • Acronyms EMERGE
  • Most Recent Events

    • 10 Aug 2017 According to a 4SC media release, the company anticipates to initiate this study in the second half of 2017.
    • 16 May 2017 According to a 4SC media release, results from this study are expected in 2019.
    • 31 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top